SCHEMBL2272929

SCHEMBL2272929

CC(=O)c1ccc(/C=C/c2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.55
MEN1 O00255 4/20 0.55
PKM P14618 3/20 0.55
MAPT P10636 2/20 0.55
GRIK1 P39086 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
HDAC2 Q92769 1/20 0.50
PTPN1 P18031 1/20 0.49
AKR1B10 O60218 1/20 0.49
AKR1B1 P15121 1/20 0.49
AKR1C4 P17516 1/20 0.49
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
SNCA P37840 5/20 0.48
POLB P06746 2/20 0.48
DHODH Q02127 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272933 1.00 KMT2A (0.55) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2276655 0.91 PKM (0.62) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2276651 0.91 PKM (0.62) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2270230 0.87 KMT2A (0.57) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2270237 0.87 KMT2A (0.57) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2276918 0.86 SNCA (0.66) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2276923 0.86 SNCA (0.66) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2273661 0.85 SNCA (0.68) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL2273655 0.85 SNCA (0.68) KMT2AMEN1PKMMAPTGRIK1
SCHEMBL27716652 0.85 SNCA (0.63) KMT2AMEN1PKMMAPTGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 KMT2A 1669/4885MEN1 3105/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.